4D Molecular Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TREND4D Molecular Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings contraction of 17% provides fundamental context to the price action. However, price is extended 29% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.77 | +19.04% | ABOVE |
| 50 SMA | $9.93 | +29.04% | ABOVE |
| 100 SMA | $9.65 | +32.88% | ABOVE |
| 150 SMA | $9.40 | +36.41% | ABOVE |
| 200 SMA | $9.53 | +34.50% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is FDMT in an uptrend right now?
FDMT has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is FDMT overbought or oversold?
FDMT's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is FDMT outperforming the market?
FDMT has a Relative Strength (RS) Rating of 89 out of 99. Yes, FDMT is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is FDMT in its 52-week range?
FDMT is trading at $12.82, which is 92% of its 52-week high ($14.01) and 88% above its 52-week low ($3.98).
How volatile is FDMT?
FDMT has a Beta of 1.37 and 52-week volatility of 92%. It's more volatile than the S&P 500 - expect bigger swings.